CN102977208A - Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit - Google Patents
Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit Download PDFInfo
- Publication number
- CN102977208A CN102977208A CN2012105364081A CN201210536408A CN102977208A CN 102977208 A CN102977208 A CN 102977208A CN 2012105364081 A CN2012105364081 A CN 2012105364081A CN 201210536408 A CN201210536408 A CN 201210536408A CN 102977208 A CN102977208 A CN 102977208A
- Authority
- CN
- China
- Prior art keywords
- preparation
- acinetobacter bauamnnii
- group
- yolk
- igy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as a preparation and a kit. The preparation method is characterized by comprising the following steps of: preparing antigen liquor, immunizing hens, and separating and purifying the IgY. In-vivo and in-vitro experiments prove that the prepared specificity IgY has specific binding activity to the acinetobacter baumannii, can be used for effectively inhibiting the growth of the acinetobacter baumannii and alleviating a toxic effect generated by the acinetobacter baumannii, can be applied to prevention, treatment and diagnostic analysis on infectious diseases and complications of the acinetobacter baumannii, and has wide application prospect.
Description
Technical field
The invention belongs to biological technical field, be specifically related to a kind of preparation method, application and pharmaceutical composition, preparation and test kit of Acinetobacter bauamnnii special yolk immunoglobulin (Ig).
Background technology
Acinetobacter bauamnnii (Acinetobacter baumannii) is non-fermentation Gram Negative Bacilli, it is the flora that causes the human infection in the acinetobacter calcoaceticus, mainly cause respiratory tract infection, microbemia, urinary system infection, wound infection, meningitis etc., also can cause peritonitis, endocarditis, endophthalmitis etc., modal infection site is lung, is the important pathogenic former of Nosocomial Pneumonia.
A large amount of uses along with clinical antibacterials, the resistance of Acinetobacter bauamnnii is also more and more stronger, multi-drug resistant is appearred in the Common Antibiotics such as cephalosporins, aminoglycoside, quinolones, even the mould class medicine of the blue or green alkene of carbon comprised that resistance all appears in imipenum or Meropenem, this brings very big difficulty to clinical treatment.
Yolk immunoglobulin (Egg yolk immunoglobulin, IgY) be the bird bone-marrow-derived lymphocyte antigenic substance stimulate lower produces and is deposited in the yolk can with a kind of immunoglobulin (Ig) of antigen generation specific reaction, be the material for the raising resistibility that bird forms in the long-term evolution process.IgY compares with chemicals and to have no side effect except having the advantages such as high specificity, cheap and easy to get, stable in properties, compares with microbiotic to be difficult for producing resistance, thereby gains great popularity.U.S. FDA has been considered as special yolk antibody the primary drug candidate of substitute antibiotics, and Japanese government drops into huge fund and helps " fowl source antibody industry ".
At present, multiple specific IgY is obtaining application aspect human and animal's prevention and treatment of diseases.The application of specific IgY in the human diseases control comprises infants with rotavirus diarrhoea, helicobacter pylori infection, carious tooth etc., but the application in the control of Acinetobacter bauamnnii infectious diseases yet there are no report.
Summary of the invention
The preparation method and application and the pharmaceutical composition that is prepared by this IgY, preparation and the test kit that the purpose of this invention is to provide a kind of Acinetobacter bauamnnii special yolk immunoglobulin (Ig) (IgY).
Particularly, the preparation method of described Acinetobacter bauamnnii special yolk immunoglobulin (Ig) of the present invention comprises the steps:
(1) modulation antigen liquid
With the Acinetobacter bauamnnii bacterial classification inoculation in the TSB liquid nutrient medium, 37 ℃ cultivate 18-24h after, centrifugal collection thalline, thalline is with normal saline dilution to 10
8-10
10Cfu/mL adds the formaldehyde of bacteria liquid long-pending 0.5% in the bacterium liquid, and 37 ℃ of deactivation 24h shake frequently, add respectively isopyknic Freund's complete adjuvant or Freund's incomplete adjuvant after steriling test is qualified, makes full bacterium inactivated vaccine, 4 ℃ of preservations after fully emulsified;
(2) immune hen
Select the bird inlay of 140-160 age in days, in every thoracic muscle inject 2 points, immunity is carried out in 1 of neck subcutaneous injection, immunity is three times altogether, the vaccine of first immunisation is for adding the antigen liquid of Freund's complete adjuvant, the vaccine of booster immunization is for adding the antigen liquid of Freund's incomplete adjuvant, and three times immunizing dose increases progressively, and is respectively every chicken 1.0mL, 1.5mL and 2.0mL, each immune interval 14 days, 1-160 days egg is preserved in 4 ℃ of classification after the collection first immunisation;
(3) separation, purifying Yolk immunoglobulin
Get immune egg, clean sterilization, shell breaking, remove albumen with Yolk separator, then further draw albumen with aseptic filter paper, puncture membrane of yolk and collect yolk, yolk liquid adds the deionized water dilution of 6-10 times of volume, transfer pH to 5.0 with hydrochloric acid, stir evenly rear 4 ℃ of placements and spend the night, at 4 ℃ of centrifugal 25min of lower 10000rpm, get supernatant liquor, after saltouing, the solution of saltouing gets lyophilized powder through ultrafiltration, lyophilize.
Wherein, described Acinetobacter bauamnnii bacterial classification can use commercially available Acinetobacter bauamnnii standard bacterium, also can use hospital distributing from the multidrug resistance Acinetobacter bauamnnii that obtains.
The Acinetobacter bauamnnii special yolk immunoglobulin (Ig) that described application of the present invention comprises above-mentioned preparation is for the preparation of the application in the medicine of control Acinetobacter bauamnnii infectious diseases with for the preparation of the application in the medicine of analyzing and diagnosing Acinetobacter bauamnnii infectious diseases.
In above-mentioned application, described Acinetobacter bauamnnii infectious diseases generally refers to one or more in the infective respiratory tract infection of Acinetobacter bauamnnii, microbemia, urinary system infection, wound infection, meningitis, peritonitis, endocarditis, the endophthalmitis, refers in particular to Acinetobacter bauamnnii infectious pneumonia or microbemia.
The present invention also provides a kind of pharmaceutical composition and preparation thereof.Described pharmaceutical composition comprises Acinetobacter bauamnnii special yolk immunoglobulin (Ig) and the pharmaceutically acceptable auxiliary material of above-mentioned preparation.Described preparation is the preparation that is prepared by aforementioned pharmaceutical compositions, is oral preparations, injection formulations or external preparation, comprises tablet, capsule, microcapsule, injection, transfusion, ointment etc.
As tablet, can and tire according to therapeutic dose, an amount of above-mentioned Acinetobacter bauamnnii special yolk Sandoglobulin is mixed with weighting agent (such as amylum pregelatinisatum), disintegrating agent (such as Microcrystalline Cellulose), lubricant (such as micropowder silica gel, talcum powder), then compressing tablet or direct compression behind the dry granulation carry out dressing as required.As capsule, can and tire according to therapeutic dose, an amount of above-mentioned Acinetobacter bauamnnii special yolk Sandoglobulin and weighting agent (such as dextrin) are mixed, insert capsule.As microcapsule, can and tire according to therapeutic dose, with the solution of an amount of above-mentioned Acinetobacter bauamnnii special yolk immunoglobulin (Ig) and capsule material (such as the Tisuacryl monomer) according to the emulsion polymerization two-step approach, take PLURONICS F87 as stablizer, make nanocapsule or micro-capsule, then further make other formulation.As injection, the solution of certain density above-mentioned Acinetobacter bauamnnii special yolk immunoglobulin (Ig) can be mixed with isotonic regulator (such as glucose), stablizer (such as halfcystine), 0.1 μ m Entkeimung is according to therapeutic dose and the packing of tiring.As ointment, can and tire according to therapeutic dose, an amount of above-mentioned Acinetobacter bauamnnii special yolk immunoglobulin (Ig) and blank ointment base (such as the mixture that is comprised of Macrogol 4000 and poly(oxyethylene glycol) 400) and sanitas (such as ethyl p-hydroxybenzoate) are mixed be prepared.
In addition, the Acinetobacter bauamnnii special yolk immunoglobulin (Ig) of the present invention preparation can also test kit form provide, the Acinetobacter bauamnnii special yolk immunoglobulin (Ig) that comprises above-mentioned preparation in the described test kit can also comprise other various additives such as enzyme substrates and stablizer, buffer reagent etc.
The vivo and vitro experiment shows, the specific IgY that the present invention prepares and Acinetobacter bauamnnii have the specific combination activity, growth that can the establishment Acinetobacter bauamnnii and the toxic effect of generation thereof, can be used for control and the diagnositc analysis of Acinetobacter bauamnnii infectious diseases and complication thereof, have broad application prospects.
Description of drawings
Fig. 1 is that M group and Q organize the electrophorogram that respectively goes on foot the specific IgY behind the purifying.Band among the figure: the ultrafiltration component of 1.M group-specific IgY; The component 2.M the secondary of group-specific IgY is saltoutd; 3.IgY standard substance; 4.M the component of once saltouing of group-specific IgY; 5.M the water soluble ingredient of group-specific IgY; 6.Q the ultrafiltration component of group-specific IgY; The component 7.Q the secondary of group-specific IgY is saltoutd; 8.Q the component of once saltouing of group-specific IgY; 9.Q the water soluble ingredient of group-specific IgY.
Fig. 2 represents the antibody titer with different time yolk water soluble ingredient after the M group-specific IgY immunity.
Fig. 3 represents the antibody titer with different time yolk water soluble ingredient after the Q group-specific IgY immunity.
Fig. 4 represents that M group-specific IgY is to the growth-inhibiting effect of M bacterium.
Fig. 5 represents that Q group-specific IgY is to the growth-inhibiting effect of M bacterium.
Fig. 6 represents that M group-specific IgY is to the growth-inhibiting effect of Q bacterium.
Fig. 7 represents that Q group-specific IgY is to the growth-inhibiting effect of Q bacterium.
Embodiment
One, the preparation of IgY
Adopt respectively the Acinetobacter bauamnnii of two kinds of different sourcess as the antigen immune hen in the following examples 1,2, prepare two kinds of Acinetobacter bauamnnii specific IgYs, respectively called after M group and Q group.
Embodiment 1(M group-specific IgY)
(1) modulation antigen liquid
With Acinetobacter bauamnnii standard bacterium (ATCC-BAA1605, available from the biological product collecting center (American type culture collection) of USS, Dalian occasion treasure biochemical reagents company sells) (be called for short M bacterium) be inoculated in the TSB liquid nutrient medium, behind 37 ℃ of cultivation 20h, collect thalline in the centrifugal 15min of 6000rpm, thalline is with normal saline dilution to 10
9Cfu/ml, the blood counting chamber counting.Then add the formaldehyde of bacteria liquid long-pending 0.5% in the bacterium liquid, 37 ℃ of deactivation 24h shake frequently.After steriling test is qualified, add respectively isopyknic Freund's complete adjuvant or Freund's incomplete adjuvant, make full bacterium inactivated vaccine, 4 ℃ of preservations after fully emulsified.Vaccine then needs to use behind the abundant mixing as demixing phenomenon occurs before the injection.
(2) immune hen
Select bird inlay (the sea blue laying hen of 140-160 age in days, available from Dalian Hong Jia herding company limited), in every thoracic muscle inject 2 points, immunity is carried out in 1 of neck subcutaneous injection, immunity is three times altogether, the vaccine of first immunisation is for adding the antigen liquid of Freund's complete adjuvant, the vaccine of booster immunization is for adding the antigen liquid of Freund's incomplete adjuvant, three times immunizing dose increases progressively, be respectively every chicken 1.0mL, 1.5mL and 2.0mL, each immune interval 14 days, 1-160 days egg is preserved in 4 ℃ of classification after the collection first immunisation.
(3) separation, purifying Yolk immunoglobulin
Get sorted immune egg, clean sterilization, shell breaking is removed albumen with Yolk separator, then further draws albumen with aseptic filter paper, punctures membrane of yolk and collects yolk.Yolk liquid adds the deionized water dilution of 6 times of volumes, transfers pH to 5.0 with hydrochloric acid, stirs evenly rear 4 ℃ of placements and spends the night, and at 4 ℃ of centrifugal 25min of lower 10000rpm, getting supernatant liquor is water soluble ingredient (WSF).Saltout by ammoniumsulphate soln, the 14wt% metabisulfite solution of 50% saturation ratio first, the solution of saltouing gets lyophilized powder through ultrafiltration (Vivaflow50 ultrafiltration system, molecular weight cut-off are 100KD), lyophilize again.
Embodiment 2(Q group-specific IgY)
Hospital distributing is processed the modulation antigen liquid by same method from the multidrug resistance Acinetobacter bauamnnii that obtains (being called for short the Q bacterium).Other steps prepare the Yolk immunoglobulin lyophilized powder similarly to Example 1.
The non-specific IgY of embodiment 3()
Except bacterium liquid is replaced with the physiological saline, the method by similarly to Example 1 prepares the Yolk immunoglobulin lyophilized powder.
Two, purity detecting
Adopt the SDS-PAGE(damping fluid to adopt Tris-glycine system, resolving gel concentration is 7.5%, and concentrated gum concentration is 4%), in the specific IgY purity (as shown in Figure 1) that detects under the non-reduced condition after respectively going on foot purifying.
As can be seen from Figure 1, separation obtains yolk antibody through water dilution method, saltouts the purge process of last ultrafiltration desalination for twice through ammonium sulfate and sodium sulfate again, antibody purity progressively improves, and the saltout purity of component of ultrafiltration and secondary has surpassed IgY standard substance (available from Promega company).
Three, bioactivity
Adopt the antibody titer in the rear different time yolk water soluble ingredient (WSF) of indirect elisa method mensuration immunity, concrete steps are as follows: (the 0.05M carbonate buffer solution, pH9.6) diluting antigen bacteria (M bacterium or Q bacterium) to concentration is 10 with coated damping fluid
9Cfu/mL, coated elisa plate (every hole 100 μ L), 37 ℃ of incubation 2h, washings (the PBS solution of 0.05%Tween20) is washed plate three times; Confining liquid (the PBS solution of 1%BSA) sealing (every hole 100 μ L), 37 ℃ of incubation 1h, washings wash plate three times; Add respectively with diluent (the PBS solution of the 0.1%BSA) specific IgY of doubling dilution or the every hole 100 μ L of the WSF(of non-specific IgY), with the negative contrast of WSF of immune group egg not, with the serum (extracting vein blood on the same day of three immunity, the serum that obtains in the centrifugal 10min of 5000rpm) positive contrast, take diluent as blank (negative control, positive control and blank are respectively every hole 100 μ L), 37 ℃ of incubation 2h, washings wash plate three times; Add the anti-chicken IgG(of HRP mark rabbit available from Sigma company) (every hole 100 μ L), 37 ℃ of incubation 1h, washings wash plate three times; Add TMB working fluid (available from Huamei Bio-Engrg Co.) (every hole 100 μ L), shady place reaction 20min; Add 2M H
2SO
4Stop (every hole 50 μ L), microplate reader detects OD value (detecting wavelength 450nm).2.1 times of corresponding maximum dilution multiples of the negative control value of OD value are as its valence value (result of M group-specific IgY as shown in Figure 2, the result of Q group-specific IgY as shown in Figure 3).
As can be seen from Figure 2, M group all 10 days after the first immunisation is tired and is begun to raise, and tires in 25 days to reach 12800,30 ~ 55 days and reach peak value to be 25600, and high-titer (more than 6400) may persist to rear 120 days of immunity.As seen from Figure 3, Q group also 10 days after the first immunisation is tired and is begun to raise, and tires in 25 days to reach 12800,40 ~ 60 days and reach peak value to be 25600, and high-titer (more than 6400) may persist to rear 120 days of immunity.And physiological saline immune group IgY(is non-specific IgY) to tire be 200 always, illustrating does not have specific IgY to produce.
Four, bacteriostatic experiment
5,10,20mg/mL specific IgY lyophilized powder (M group or Q group) is dissolved in the TSB liquid nutrient medium to desired concn:, in addition, non-specific IgY lyophilized powder is dissolved in the TSB liquid nutrient medium to 10mg/mL(negative control 1), cefoperzone sodium and sulbactam sodium is dissolved in the TSB liquid nutrient medium to the 0.2mg/mL(positive control), get in addition TSB liquid nutrient medium (negative control 2), respectively with these solution through 0.22 μ m filtering with microporous membrane degerming.M bacterium or Q bacterium are joined respectively in the mentioned solution, and making the bacterium final concentration is 10
7Cfu/mL is hatched under 37 ℃, 80rpm concussion speed, every the 2h 100 μ L that take a sample, take the blank of TSB liquid nutrient medium as measuring, adopts microplate reader to measure light absorption value (detecting wavelength 600nm), and the result is shown in Fig. 4-7.
Fig. 4 represents M group-specific IgY to the growth-inhibiting effect of M bacterium, and Fig. 5 represents that Q group-specific IgY is to the growth-inhibiting effect of M bacterium.Can find out that from Fig. 4,5 specific IgY that M group and Q organize is 5,10 and all can suppresses the growth of M bacterium during 20mg/mL fully in concentration, basic identical with positive control medicine bacteriostatic action, but not specific IgY does not have restraining effect to the growth of M bacterium.
Fig. 6 represents M group-specific IgY to the growth-inhibiting effect of Q bacterium, and Fig. 7 represents that Q group-specific IgY is to the growth-inhibiting effect of Q bacterium.Can find out from Fig. 6,7, M group-specific IgY concentration be 5,10 and during 20mg/mL the growth-inhibiting effect to the Q bacterium be dose-dependently; Q group-specific IgY concentration be 5,10 and during 20mg/mL the growth-inhibiting effect to the Q bacterium also be dose-dependently, when concentration is 20mg/mL, can suppress the growth of Q bacterium fully.
Five, to the effect of mouse pneumonia
Get 50 of Kunming mouses (Dalian Medical Univ's Experimental Animal Center, credit number SCXK(the Liao Dynasty) 2008-0002), be divided at random 5 groups, 10 every group.4 groups of mouse intranasals splash into Acinetobacter bauamnnii (Q bacterium) (2 * 10
11Cfu/mL, 50 μ L/10g body weight) set up murine pneumonia model; 1 group as the blank group, does not infect Acinetobacter bauamnnii.
Cefoperzone sodium and sulbactam sodium, specific IgY (M group or Q group) respectively with physiological saline solution to desired concn (cefoperzone sodium and sulbactam sodium 20mg/mL, specific IgY 20mg/mL), with for subsequent use after the 0.22 μ m filtering with microporous membrane degerming.
Each organizes mouse respectively at 24h intraperitoneal injection before infecting once, every 10g body weight 150 μ L; And after infection every the 24h intraperitoneal injection once, continuous five days, every 10g body weight 250 μ L.The medicine that each group gives is as shown in table 1.
Observe clinical manifestation, body weight, body temperature variation, the variation of white corpuscle (WBC) number, mortality ratio, lung tissue microbial culture, lung tissue outward appearance and the lung pathology section of respectively organizing mouse.After Acinetobacter bauamnnii infected, except the blank group, each organizes WBC number average in Mouse Weight, body temperature, the peripheral blood in various degree decline, and the decline of specific IgY (M group and Q organize) treatment group is starkly lower than negative control group, and is close with positive controls; Except the blank group, all the other are respectively organized the cultivation of mouse lung tissue bacterial and all are positive, and specific IgY (M group and Q group) treatment group and positive controls bacterial count are lower than negative control group; Except the blank group, all the other respectively organize the mouse lung tissue appearance in various degree damage, and the lung pathology section shows that alveolar structure destroys, pulmonary fibrosis, but specific IgY (M group and Q organize) treatment group and positive controls degree of injury are lower than negative control group; Each is organized four days mortality ratio of mouse and is respectively: the blank group is 0, and negative control group is 90%, and positive controls and specific IgY treatment group are 20%.
Table 1
| Group | Mouse | The medicine that gives |
| The blank group | Pneumonia infection not | Physiological saline |
| Negative control group | Pulmonary inflammation model | Physiological saline |
| Positive controls | Pulmonary inflammation model | Cefoperzone sodium and sulbactam sodium |
| Specific |
Pulmonary inflammation model | M group-specific IgY |
| Specific |
Pulmonary inflammation model | Q group-specific IgY |
Six, formulation examples
1. tablet: specific IgY (M group or Q group) lyophilized powder 10g and amylum pregelatinisatum 375g, Microcrystalline Cellulose 100g, micropowder silica gel 15g are mixed, and compressing tablet behind the dry granulation is made 1000 altogether.
2. capsule: specific IgY (M group or Q group) lyophilized powder 10g and dextrin 490g are mixed, insert capsule, make altogether 1000.
3. microcapsule: with specific IgY (M group or Q group) solution 40mL(25mg/mL) with Tisuacryl monomer 10g according to the emulsion polymerization two-step approach, take PLURONICS F87 as stablizer, make micro-capsule.
4. ointment: with 25g Macrogol 4000 and 64.9g poly(oxyethylene glycol) 400 heating and melting, add the 0.1g ethyl p-hydroxybenzoate and make its dissolving, then under agitation be cooled to rapidly about 35 ℃, add 10ml specific IgY (M group or Q group) solution (100mg/ml), stir and get final product.
5. injection: lactose 1g, glucose 4.5g, halfcystine 0.05g are dissolved in a small amount of water, add specific IgY (M group or Q group) solution 40ml(25mg/ml), add water and be settled to 100ml, 0.1 be sub-packed in ampoule behind the μ m filtering with microporous membrane, every bottle of 1ml, sealing and leak detection after the lyophilize.
Claims (9)
1. the preparation method of an Acinetobacter bauamnnii special yolk immunoglobulin (Ig) is characterized in that, comprises the steps:
(1) modulation antigen liquid
With the Acinetobacter bauamnnii bacterial classification inoculation in the TSB liquid nutrient medium, 37 ℃ cultivate 18-24h after, centrifugal collection thalline, thalline is with normal saline dilution to 10
8-10
10Cfu/mL adds the formaldehyde of bacteria liquid long-pending 0.5% in the bacterium liquid, and 37 ℃ of deactivation 24h shake frequently, add respectively isopyknic Freund's complete adjuvant or Freund's incomplete adjuvant after steriling test is qualified, makes full bacterium inactivated vaccine, 4 ℃ of preservations after fully emulsified;
(2) immune hen
Select the bird inlay of 140-160 age in days, in every thoracic muscle inject 2 points, immunity is carried out in 1 of neck subcutaneous injection, immunity is three times altogether, the vaccine of first immunisation is for adding the antigen liquid of Freund's complete adjuvant, the vaccine of booster immunization is for adding the antigen liquid of Freund's incomplete adjuvant, and three times immunizing dose increases progressively, and is respectively every chicken 1.0mL, 1.5mL and 2.0mL, each immune interval 14 days, 1-160 days egg is preserved in 4 ℃ of classification after the collection first immunisation;
(3) separation, purifying Yolk immunoglobulin
Get immune egg, clean sterilization, shell breaking, remove albumen with Yolk separator, then further draw albumen with aseptic filter paper, puncture membrane of yolk and collect yolk, yolk liquid adds the deionized water dilution of 6-10 times of volume, transfer pH to 5.0 with hydrochloric acid, stir evenly rear 4 ℃ of placements and spend the night, at 4 ℃ of centrifugal 25min of lower 10000rpm, get supernatant liquor, after saltouing, the solution of saltouing gets lyophilized powder through ultrafiltration, lyophilize.
2. preparation method according to claim 1 is characterized in that, described Acinetobacter bauamnnii bacterial classification is commercially available Acinetobacter bauamnnii standard bacterium.
3. preparation method according to claim 1 is characterized in that, described Acinetobacter bauamnnii bacterial classification is that hospital distributing is from the multidrug resistance Acinetobacter bauamnnii that obtains.
Among the claim 1-3 Acinetobacter bauamnnii special yolk immunoglobulin (Ig) of any one preparation for the preparation of the application in the medicine of control or analyzing and diagnosing Acinetobacter bauamnnii infectious diseases.
5. application according to claim 4, it is characterized in that described Acinetobacter bauamnnii infectious diseases is one or more in the infective respiratory tract infection of Acinetobacter bauamnnii, microbemia, urinary system infection, wound infection, meningitis, peritonitis, endocarditis, the endophthalmitis.
6. application according to claim 5 is characterized in that, described Acinetobacter bauamnnii infectious diseases is Acinetobacter bauamnnii infectious pneumonia or microbemia.
7. a pharmaceutical composition is characterized in that, described pharmaceutical composition comprises Acinetobacter bauamnnii special yolk immunoglobulin (Ig) and the pharmaceutically acceptable auxiliary material of any one preparation among the claim 1-3.
8. a preparation that is prepared by pharmaceutical composition claimed in claim 7 is characterized in that, described preparation is oral preparations, injection formulations or external preparation.
9. a test kit is characterized in that, described test kit comprises the Acinetobacter bauamnnii special yolk immunoglobulin (Ig) of any one preparation among the claim 1-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210536408.1A CN102977208B (en) | 2012-12-12 | 2012-12-12 | Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210536408.1A CN102977208B (en) | 2012-12-12 | 2012-12-12 | Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102977208A true CN102977208A (en) | 2013-03-20 |
| CN102977208B CN102977208B (en) | 2015-04-08 |
Family
ID=47851587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210536408.1A Expired - Fee Related CN102977208B (en) | 2012-12-12 | 2012-12-12 | Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102977208B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103992403A (en) * | 2014-05-23 | 2014-08-20 | 安徽科技学院 | Method for removing lipoprotein and lipid in goose/duck yolk by using freezing method |
| CN104725492A (en) * | 2015-04-18 | 2015-06-24 | 吉林大学 | Immunity-protective Acinetobacter baumannii surface antigen SurAl |
| CN104829713A (en) * | 2014-05-27 | 2015-08-12 | 青岛大学附属医院 | Preparation and application of egg yolk immunoglobulin with specificity and fusarium infection resistance |
| CN105418759A (en) * | 2015-12-07 | 2016-03-23 | 河南大学 | Actinomyces naeslundii-resistant egg yolk antibody and preparation method thereof |
| CN107073095A (en) * | 2014-05-05 | 2017-08-18 | 瓦克斯丁公司 | The anti-Acinetobacter baumannii vaccine of the cellular component lacked based on lipopolysaccharides |
| CN108472372A (en) * | 2015-07-13 | 2018-08-31 | 海港医学中心洛杉矶生物医学研究所 | In conjunction with the antibody conjugate and application thereof of acinetobacter calcoaceticus |
| CN108992669A (en) * | 2018-08-27 | 2018-12-14 | 广州汇高生物科技有限公司 | Composite yolk antibody composition, aerosol inhalation solution agent and the preparation process and application for preventing and treating respiratory tract infection |
| CN109010824A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of special yolk immune globulin composite and its preparation |
| CN110787293A (en) * | 2018-08-03 | 2020-02-14 | 广州汇高生物科技有限公司 | Antibacterial cleaning composition for wound and wound plaster |
| CN111060684A (en) * | 2019-12-31 | 2020-04-24 | 锐纳生物技术(杭州)有限公司 | In-vitro diagnostic kit preservative with dual effects |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101052418A (en) * | 2004-09-29 | 2007-10-10 | 浅间化成株式会社 | Functional composition or food comprising whey protein and antibody derived from milk or antibody |
| CN102188449A (en) * | 2011-04-15 | 2011-09-21 | 广西壮族自治区兽医研究所 | Preparation method of high-immune whole-egg powder for resisting piglet diarrhea |
| CN102617731A (en) * | 2012-04-19 | 2012-08-01 | 华中农业大学 | Porcine circovirus-resistant type 2 egg yolk antibody and preparation method and application thereof |
-
2012
- 2012-12-12 CN CN201210536408.1A patent/CN102977208B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101052418A (en) * | 2004-09-29 | 2007-10-10 | 浅间化成株式会社 | Functional composition or food comprising whey protein and antibody derived from milk or antibody |
| CN102188449A (en) * | 2011-04-15 | 2011-09-21 | 广西壮族自治区兽医研究所 | Preparation method of high-immune whole-egg powder for resisting piglet diarrhea |
| CN102617731A (en) * | 2012-04-19 | 2012-08-01 | 华中农业大学 | Porcine circovirus-resistant type 2 egg yolk antibody and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| K. HANCE ET AL: "A Rapid Indirect Enzyme-Linked Immunosorbent Assay for Identification of Acinetobacter spp. From Cultured Isolates", 《HTTP://ACCELERATEDIAGNOSTICS.COM/DOCS/ASM_2008_ELISA_C065.PDF》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107073095A (en) * | 2014-05-05 | 2017-08-18 | 瓦克斯丁公司 | The anti-Acinetobacter baumannii vaccine of the cellular component lacked based on lipopolysaccharides |
| CN103992403A (en) * | 2014-05-23 | 2014-08-20 | 安徽科技学院 | Method for removing lipoprotein and lipid in goose/duck yolk by using freezing method |
| CN104829713A (en) * | 2014-05-27 | 2015-08-12 | 青岛大学附属医院 | Preparation and application of egg yolk immunoglobulin with specificity and fusarium infection resistance |
| CN104844709A (en) * | 2014-05-27 | 2015-08-19 | 青岛大学附属医院 | Preparation for specific aspergillus fumigatus infection resisting chicken egg yolk antibody and application |
| CN104725492B (en) * | 2015-04-18 | 2017-08-25 | 吉林大学 | A kind of Acinetobacter bauamnnii surface antigen S urA1 with immune protective |
| CN104725492A (en) * | 2015-04-18 | 2015-06-24 | 吉林大学 | Immunity-protective Acinetobacter baumannii surface antigen SurAl |
| CN108472372A (en) * | 2015-07-13 | 2018-08-31 | 海港医学中心洛杉矶生物医学研究所 | In conjunction with the antibody conjugate and application thereof of acinetobacter calcoaceticus |
| CN108472372B (en) * | 2015-07-13 | 2022-05-17 | 海港医学中心洛杉矶生物医学研究所 | Acinetobacter-binding antibody binding agents and uses thereof |
| CN105418759A (en) * | 2015-12-07 | 2016-03-23 | 河南大学 | Actinomyces naeslundii-resistant egg yolk antibody and preparation method thereof |
| CN105418759B (en) * | 2015-12-07 | 2019-05-21 | 河南大学 | A kind of anti-actinomyces naeslundii Yolk antibody and preparation method thereof |
| CN110787293A (en) * | 2018-08-03 | 2020-02-14 | 广州汇高生物科技有限公司 | Antibacterial cleaning composition for wound and wound plaster |
| CN108992669A (en) * | 2018-08-27 | 2018-12-14 | 广州汇高生物科技有限公司 | Composite yolk antibody composition, aerosol inhalation solution agent and the preparation process and application for preventing and treating respiratory tract infection |
| CN109010824A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of special yolk immune globulin composite and its preparation |
| CN111060684A (en) * | 2019-12-31 | 2020-04-24 | 锐纳生物技术(杭州)有限公司 | In-vitro diagnostic kit preservative with dual effects |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102977208B (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102977208B (en) | Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit | |
| CN106380518A (en) | Extraction technology of egg yolk immunoglobulins | |
| US20220267419A1 (en) | Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof | |
| CN110812474A (en) | Triple inactivated vaccine for porcine circovirus type 2, mycoplasma hyopneumoniae and haemophilus parasuis and preparation method thereof | |
| DE2817299A1 (en) | METHOD OF PRODUCING ATTENUATED INFECTIOUS GASTROENTERITIS (TGE) VIRUS STRAIN FOR USE IN LIVE VACCINES | |
| US20020009429A1 (en) | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods | |
| CN104383528B (en) | Pig epidemic diarrhea inactivated vaccine and preparation method thereof | |
| CN1454901A (en) | Gynaecological anti-infective specificity IgY and its combined preparation | |
| CN101259275A (en) | Yolk antibody feed additive and injection for resisting sheep virosis and preparation thereof | |
| TW403655B (en) | Novel attenuated pseudomonas aeruginosa strains | |
| JPH08504167A (en) | Directed human immunoglobulins for prevention and treatment of Staphylococcus infection | |
| CN101766814A (en) | Swine pasteurellosis bivalent inactivated vaccine and preparation method thereof | |
| JP2005502594A (en) | Anti-dandruff immunity antibody and its use | |
| RU2438709C1 (en) | Serum against cattle diseases caused by viruses of infectious rhinotracheatis, paraflu, rota, corona and mucosa diarrhea-disease, polyspecific, hyperimmune, method of prevention and treatment of cattle diseases caused by viruses of infectious rhinotracheitis, parainfluenza, rota, corona and mucosa diarrhea-disease | |
| US20210252148A1 (en) | Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine | |
| KR101411995B1 (en) | Antibody composition of bovine colostrum for treating or preventing porcine wasting diseases | |
| CN1384119A (en) | Composite yolk antibody for resisting fowl's viral blight and its prepn and application | |
| CN1354187A (en) | Hen egg yolk antibody for resisting pyloric helicobacterium cytotoxin, its preparation and application | |
| CN110172096A (en) | A kind of preparation method of Riemerlla anatipestifer monoclonal antibody | |
| RU2708891C1 (en) | Vaccine for rota-, coronaviral infection and cattle colibacillosis | |
| JP2000509961A (en) | Opsonizing antibodies broadly react with common staphylococcal antigens | |
| CN111620947B (en) | Preparation method of divalent sea snake poison resisting serum | |
| CN102770452A (en) | An IgY for a PA-MSHA bacterial strain, and preparation method and application thereof | |
| US2998349A (en) | Vaccine against avian respiratory infection | |
| RU2056861C1 (en) | Mixed vaccine against anthrax and foot-and-mouth and a method of anthrax and foot-and-mouth prophylaxis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150408 Termination date: 20171212 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |